Aaron Wealth Advisors LLC Has $457,000 Stock Position in Cencora, Inc. (NYSE:COR)

Aaron Wealth Advisors LLC boosted its position in Cencora, Inc. (NYSE:COR) by 20.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,033 shares of the company’s stock after buying an additional 339 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Cencora were worth $457,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of COR. Ieq Capital LLC boosted its stake in Cencora by 8.7% during the 2nd quarter. Ieq Capital LLC now owns 9,613 shares of the company’s stock valued at $2,166,000 after purchasing an additional 768 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Cencora by 26.3% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,809 shares of the company’s stock worth $1,759,000 after buying an additional 1,626 shares during the last quarter. Bridges Investment Management Inc. acquired a new stake in shares of Cencora in the second quarter worth $318,000. AE Wealth Management LLC increased its position in Cencora by 2.5% during the second quarter. AE Wealth Management LLC now owns 18,826 shares of the company’s stock worth $4,242,000 after acquiring an additional 468 shares during the period. Finally, Sei Investments Co. raised its stake in Cencora by 2.5% during the 2nd quarter. Sei Investments Co. now owns 275,154 shares of the company’s stock valued at $61,994,000 after purchasing an additional 6,626 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.5 %

COR opened at $242.11 on Monday. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $253.27. The firm has a 50-day moving average price of $237.52 and a two-hundred day moving average price of $234.01. The stock has a market capitalization of $46.80 billion, a PE ratio of 32.24, a PEG ratio of 1.48 and a beta of 0.49. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is presently 29.29%.

Analysts Set New Price Targets

Several research firms recently weighed in on COR. Wells Fargo & Company reduced their target price on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Robert W. Baird lifted their price objective on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target on the stock. Finally, Leerink Partners dropped their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $275.60.

Insider Activity

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock valued at $22,862,734 over the last 90 days. 15.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.